Gilead-Teva IP Deal Struck Despite Invalidity Issues, Jury Told
Two experts took the stand Friday on behalf of indirect drug buyers in a California federal antitrust trial over claims Teva struck an illegal "pay for delay" patent deal with Gilead...To view the full article, register now.
Already a subscriber? Click here to view full article